65,437 trials
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
Exocrine Pancreatic Insufficiency · Cystic Fibrosis
Primary: Safety — 3; 0 Participants
Biliary Atresia
Primary: Feasibility of IVIG Treatment — 23 Participants
HIV
Primary: Number of Men Who Have Sex With Men (MSM) Reporting HIV Testing in the Past Three Months — 56; 85; 122; 128 Participants
Respiratory Syncytial Virus Infection
Primary: Time-weighted Average Change in Nasal Respiratory Syncytial Viral (RSV) Load From Baseline to Day 9 — -1.00; -0.97 log10 copies/mL — p=0.94
Severe Symptomatic Calcified Native Aortic Valve Stenosis
Primary: Reduction in Median Total New Lesion Volume in Protected Territories Between Test and Control Arms as Assessed by DW-MRI at Day 2-7 Post-procedure. — 109.1; 174 mm3
Coronary Artery Disease
Primary: Comparing Measurement of Fractional Flow Reserve (FFR) — .83; .84 FFR
Cardiac Output
Primary: Change in Cardiac Output From Baseline to 20 Minutes Post-spinal — -2.05; -1.92 L/min
Schizophrenia · Schizoaffective Disorder
Primary: PANSS Positive and Negative Syndrome Scale for Schizophrenia — 70.08; 83.92; 72.25; 77 Scores on the scale
Hepatitis C Virus Infection · Human Immunodeficiency Virus Infection · Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 98.0 percentage of participants
Advanced Breast Cancer · Advanced Malignant Solid Tumors · Breast Neoplasms
Primary: Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel — 0; 0 Participants
Chronic Obstructive Pulmonary Disease
Primary: Safety Profile of Oral Cyclosporin A Immunotherapy in Advanced Stage Chronic Obstructive Pulmonary Disease Patients- Nephrotoxicity - Measured by Serum Creatinine…
Congenital Bleeding Disorder · Haemophilia B
Primary: Incidence of Inhibitory Antibodies Against FIX Defined as Titre Above or Equal to 0.6 BU (Bethesda Units) — 0; 0; 0; 0 Patients with inhibitory antibodies
Infections, Meningococcal
Primary: Anti-pneumococcal Antibody Concentrations — 3.43; 0.33; 3.60; 6.86 μg/mL